Virtual Library

Start Your Search

Dongyun He



Author of

  • +

    P2.14 - Targeted Therapy (ID 183)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Targeted Therapy
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.14-07 - Efficacy of Single Bevacizumab Intrapleural or Intrapericardial Injection in the Treatment of Lung Cancer-Mediated Malignant Effusion (ID 2098)

      10:15 - 18:15  |  Presenting Author(s): Dongyun He

      • Abstract

      Background

      Malignant pleural or pericardial effusion is common in lung cancer, and drug intrapleural and intrapericardial injection plays an important role in the treatment. Local injection drugs include chemotherapy drugs and sclerosing agents. Patients with chemotherapy are vulnerable to bone marrow suppression and gastrointestinal side effects, and sclerosing agents would cause severe local side effects and be forbidden in the intrapericardial injection. The level of vascular endothelial growth factor (VEGF) in the malignant effusion increases significantly, therefore injecting bevacizumab locally may achieve a good response. So we investigated the efficacy and safety of single bevacizumab intrapleural or intrapericardial injection in the treatment of non-small cell lung cancer (NSCLC)-mediated malignant effusion.

      Method

      This prospective, open-labeled, single arm, phase II clinical trial was undertaken at the First Affiliated Hospital of Guangzhou Medical University, China. Eligible patients had histologically or cytologically confirmed NSCLC with malignant pleural or pericardial effusion. Patients unsuitable for or rejecting the systemic therapy were included in. Patients could receive TKI continous treatment after TKI-resistance while only emerging malignant effusion. And lung cancer related symptoms were caused mainly by malignant effusions. Patients were administrated by single bevacizumab 100mg intrapleural or intrapericardial injection after the drainage of effusions. Lung cancer symptom scale (LCSS), efficacy and safety were evaluated before and after the treatment.

      Result

      Twenty patients with lung adenocarcinoma and two patients with lung squamous cell carcinoma were included in the study from January 2014 through March 2019. LCSS after the treatment (score 494±78, mean±SD) were significantly improved compared with that before the treatment (score 377±77, mean±SD) (paired differences: score 117±64, mean±SD, 95% CI: score 89-145, P<0.001). Malignant effusions decreased obviously three weeks after the treatment compared with those before the treatment (P<0.001). The median duration of response was 91 days (127±40 days, mean±SD) in the 14 patients receiving intrapleural injection, and 111 days (91±11days, mean±SD) in the 8 patients with intrapericardial injection. There was no significant difference in the remission time of local injection between malignant pleural and pericardial effusions (P=0.987). Moreover, no severe side effects emerged, only one patient had mildly dizziness.

      Conclusion

      Single bevacizumab intrapleural or intrapericardial injection is effective and safe in the treatment of lung cancer-mediated malignant effusion, while rapidly improving the malignant effusion-related symptoms in NSCLC patients. Certainly further more clinical trials were needed to confirm the results.